Compare HLSQ & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLSQ | IMCC |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.0K | 1.0M |
| IPO Year | 2018 | 2019 |
| Metric | HLSQ | IMCC |
|---|---|---|
| Price | $0.28 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.0M | ★ 4.8M |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 560.42 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $60.66 |
| Revenue Next Year | N/A | $6.68 |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.09 |
| 52 Week High | $0.77 | $8.65 |
| Indicator | HLSQ | IMCC |
|---|---|---|
| Relative Strength Index (RSI) | 10.69 | 40.57 |
| Support Level | N/A | $1.26 |
| Resistance Level | $0.45 | $4.15 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 8.91 | 4.99 |
Tessera Defense and Homeland Security Inc develops and acquires technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response markets - building a portfolio around the growing need for earlier, more accurate threat detection as UAVs and other autonomous systems reshape the operating environment. The Company's portfolio includes Zorronet, an AI-powered autonomous command-and-control platform, and DFSL, a developer of LADAR-based counter-UAS and perimeter security systems.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.